News | August 05, 2024
Roche closes acquisition of LumiraDx’s Point of Care technology
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Finerenone significantly reduced the composite of cardiovascular death and total (first and recurrent) heart failure events compared to placebo in addition to usual therapy
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Performed an autologous bone marrow transplant, using the patient’s own cells to reduce the chances of infection and rejection
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
GSK and Flagship to jointly fund up to $150 million upfront
Integrated Disease Surveillance Programme (IDSP) strengthened to improve disease surveillance and rapid data reporting
Campaign launched to spread awareness regarding dengue prevention and control
A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials
Subscribe To Our Newsletter & Stay Updated
